Login to Your Account

AACR 2012

Ibrutinib to B-Cell Lymphoma: Here I Come, Mutated or Not

By Anette Breindl
Science Editor

Tuesday, April 3, 2012
At last year's annual meeting of the American Society of Hematology, Pharmacyclics Inc.'s PCI-32765 wowed with its ability to fight chronic lymphocytic leukemia. This week at the annual meeting of the American Association for Cancer Research, the drug – now named ibrutinib and partnered with of Johnson & Johnson unit Janssen Research and Development LLC, in a deal that could ultimately be worth nearly $1 billion – showed its qualities in another type of cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription